

---

# Chest Pain Evaluation: Red herring or the real deal?

---

ZACHARY HARTSELL, DHA, PA-C

# Learning Objectives

---

Upon conclusion of this lecture, the participant will be able to:

1. Describe cardiac vs. non-cardiac chest pain
2. Discuss risk stratification for patients with suspected cardiac chest pain
3. Understand appropriate and optimal testing for both cardiac and non-cardiac etiologies of chest pain
4. Describe the treatment of common causes of chest pain

# Cardiac Chest Pain

---

Myocardial ischemia

- ACS
- Stable angina

Aortic dissection

Pericarditis

Myocarditis

Pericardial tamponade

Heart failure

Arrhythmia

# Mr. N

---

68-year-old male with HTN, HLD, GERD, and ongoing tobacco abuse presents to the ED with substernal chest pain.

He describes the pain as “tightness and pressure”, which began two hours ago while sitting at his desk. The pain lasted an hour and radiated to his left shoulder and arm. He is currently pain-free.

# Mr. N

---

## On exam:

- BP 145/87 (R) 141/85 (L), HR 74, RR 16, O<sub>2</sub> 99% RA
- General → WDWN. NAD. A&Ox3.
- Heart → RRR without MRG.
- Lungs → CTA B/L.
- Abdomen → +BS. Soft. ND. NT.
- Extremities → Peripheral pulses 2+ B/L. No pedal edema B/L.


What is your differential diagnosis?

# Chest Pain

---

## Common presenting complaint in all settings

- More than **8% of** ED visits each year as a result of acute CP
  - Less than 10% of these have ACS
- Approximately 1%- 20% of primary care present with chest pain
  - 2-4% of patients presenting to primary care will have ACS
- Despite recognized protocols, significant variation in management exists
  - Variation in admissions rates 54-96% of patients with CP.



# Features With Increased Probability of MI


**Table 2.** Value of Specific Components of the Chest Pain History for the Diagnosis of Acute Myocardial Infarction (AMI)

Pain Descriptor	Reference	No. of Patients	Positive Likelihood Ratio (95% CI)
Increased likelihood of AMI			
Radiation to right arm or shoulder	29	770	4.7 (1.9-12)
Radiation to both arms or shoulders	14	893	4.1 (2.5-6.5)
Associated with exertion	14	893	2.4 (1.5-3.8)
Radiation to left arm	24	278	2.3 (1.7-3.1)
Associated with diaphoresis	24	8426	2.0 (1.9-2.2)
Associated with nausea or vomiting	24	970	1.9 (1.7-2.3)
Worse than previous angina or similar to previous MI	29	7734	1.8 (1.6-2.0)
Described as pressure	29	11 504	1.3 (1.2-1.5)
Decreased likelihood of AMI			
Described as pleuritic	29	8822	0.2 (0.1-0.3)
Described as positional	29	8330	0.3 (0.2-0.5)
Described as sharp	29	1088	0.3 (0.2-0.5)
Reproducible with palpation	29	8822	0.3 (0.2-0.4)
Inframammary location	31	903	0.8 (0.7-0.9)
Not associated with exertion	14	893	0.8 (0.6-0.9)

Abbreviations: AMI, acute myocardial infarction; CI, confidence interval.



# Features With Increased Probability of MI



# Not all Chest Pain is the Same

---

## Women

- “Atypical” can be a mischaracterization
  - 2019 study of ~2000 women found “typical” chest pain is more commonly reported (77% vs 59%)- Women with typical MI systems have greater positive predictive value

## Black

- 32% higher mortality than white patients
- Symptoms less likely to be recognized and more likely to have delay in treatment
- Less likely to undergo coronary angiography than white patients
- Patients with diabetes significantly worse MACE than white patients

## Hispanic Non-Black

- Less likely to undergo coronary angiography than white patients
- CVD mortality similar to white patients

*“Non-white individuals continue to receive less guideline-concordant care and experience higher rates of MACE” Simon and Ho- 2020*

## Elderly


- Over 60% of the MIs and >80% of the MACE
- More likely to have atypical symptoms and delay in treatment than nonelderly patients

# Differential Diagnosis

	<i>Critical</i>	<i>Less Critical</i>
<i>Cardiac</i>	<i>ACS, aortic dissection</i>	<i>Pericarditis, myocarditis</i>
<i>Pulmonary</i>	<i>PE, pneumothorax</i>	<i>Pneumonia, pleurisy, pleural effusion</i>
<i>Gastrointestinal</i>	<i>Esophageal rupture, perforated ulcer</i>	<i>GERD, esophageal spasm, esophagitis, PUD, cholecystitis</i>
<i>Musculoskeletal</i>	-	<i>Costochondritis, rib fracture, cervical stenosis</i>
<i>Dermatologic</i>	-	<i>Herpes zoster</i>
<i>Psychiatric</i>	-	<i>Anxiety, panic attack</i>

# Thinking Outside the Box...

---



# Diagnostic Approach

---


## Step 1: Rule out critical conditions

- ACS → urgent ECG!
- Aortic dissection
- PE

## Step 2: Risk stratify patients for cardiac etiology

## Step 3: Evaluate for less critical conditions

# Mr. N



# Mr. N's Labs

---

13.9  
7.0 / 39.5 \ 241  
139 | 116 | 18.2 / 94  
4.1 | 19 | 0.8

	Mr. Sullivan	Reference Range
High Sensitivity Troponin	<0.010	<0.010

- ECG, CXR, and one set of cardiac enzymes are normal.
- What do you do next?

# Cardiac Enzymes

---

<b>Test</b>	<b>Onset</b>	<b>Peak</b>	<b>Duration</b>
CK (Isomers)	3-12 hours	18-24 hours	36-48 hours
Troponin T	3-12 hours	18-24 hours	Up to 10 days
Troponin High Sensitivity	2-3 hours	12- 48 hours	4-10 days



# High-Sensitivity Troponin T (hs-cTnT)

---

5<sup>th</sup> generation

High-sensitivity assays for hs-cTnT can detect levels as low as 5ng/L.

hs-cTnT  $\neq$  the current Troponin T

- The values should not be compared.
- hs-cTnT can detect lower levels.
- Shorter time intervals between repeat values
  - Possible intervals: 0, 2, and 6 hours

High-sensitivity troponin has greater early sensitivity and negative predictive value compared with conventional troponin

# How to Interpret the Values (ng/L)

---

Whole numbers not decimals

Normal or elevated - not negative or positive

99<sup>th</sup>% upper limit normal

- Male: 15 ng/L
- Female: 10 ng/L

Deltas from Time 0	
2h $\Delta$	$\leq 3$ = unchanged 4-9 = intermediate $\geq 10$ = Changing
6h $\Delta$	$\geq 12+$ = Changing

# High-Sensitivity Troponin T (hs-cTnT)

---

What about the value of a single test?

In ED

- Initial results of <5 ng/l does as a clinical predictor does have some value in low- risk patients
  - Generally, not relied upon

In primary care

- Study in the Netherlands found reduction on non-ACS patient referral by about 7% using point of care hs-TnT
  - Generally, not relied upon in the US

# Risk Stratification

---

## ED/Hospital

- Heart Score
- Timi

## Outpatient

- Marburg Heart Score
- INTERCHEST

# TIMI Risk Score

---

## Variables

- Age  $\geq 65$  years
- $\geq$  three risk factors for CHD
- Prior coronary stenosis of  $\geq 50$  percent
- ST segment deviation on admission ECG
- $\geq$  two anginal episodes in prior 24 hours
- $\uparrow$  serum cardiac biomarkers
- Aspirin use in prior seven days

# TIMI Risk Score

---

↑ TIMI risk score =  
↑ numbers of events at 14 days

All-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization

Score	Risk %
0-1	4.7
2	8.3
3	13.2
4	19.9
5	26.2
6-7	40.9

# HEART Score

- Useful to evaluate undifferentiated chest pain in the ED

	0 points	1 point	2 points
History	Incompatible with ACS	Potentially compatible with ACS	Strongly suggestive of ACS
ECG	Normal	Nonspecific repolarization abnormalities	ST depression or transient ST elevation
Age	<45	45-65	>65
Risk Factors	None	1-2 Risk Factors	3 Risk Factors or known CAD
Troponin Levels	Normal	1-3x upper limit of normal	>3x upper limit of normal

# HEART Score

---

Predicts 6 week risk of major adverse cardiac event (MACE)

- Risk of missed ACS <1%

Score	Risk	Recommendation
0-3	Low Risk	Outpatient follow up
4-6	Moderate Risk	Admission to hospital
7	High Risk	Admission to hospital



# Back to Mr. N

---

HEART score = **6**


- History: potentially compatible with ACS **(1)**
- ECG: nonspecific repolarization abnormalities **(1)**
- Age: >65 **(2)**
- Risk Factors: at least three risk factors **(2)**

# HEART Pathway

Combines the HEART score and serial cardiac troponins

**Low risk score < 4**

**High Risk score  $\geq 4$**



# Marburg Heart Score

---

Developed for outpatient use

One systematic review found that the Marburg was better than clinical judgement alone

Components (one point each)

- Sex/age
- Known CAD
- Pain with exercise
- Pain not elicited with palpation
- Patient assumes pain is cardiac

**Prevalence of CAD as cause of chest pain given overall population risk of:**

<b>Score</b>	<b>Likelihood ratio</b>	<b>2%</b>	<b>10%</b>	<b>20%</b>
0 to 1 point	0.04	0.1	0.4	0.9
2 to 3 points	0.92	1.8	9.3	18.8
4 to 5 points	11.2	18.6	55.5	73.7

# INTERCHEST Rule

---

Developed for outpatient use

## Components

- Pain reproduced by palpation -1
- Men >55 or women >65 +1
- Physician initially suspected a serious condition +1
- Chest pressure +1
- Chest pain with effort +1
- History of CAD +1

## Risk

-1 to 0	0.3%
1-2	6.9%
3+	64%

# Mr. N

---

You admit Mr. N for observation, and he is given ASA. He is monitored on cardiac telemetry overnight and has no recurrent chest pain.

A stress test is planned for the following morning...

# Inpatient Stress Testing

---

Exercise or pharmacologic stress ↑ myocardial oxygen demand and reveals an inadequate oxygen supply (hypoperfusion) in diseased coronary arteries

Mixed data inpatient vs. outpatient

? low risk patients

Poor outpatient compliance

# Modalities of Stress Testing

---

Exercise ECG: simple, widely available, low cost

- Many limitations, but may be appropriate initial test in some

Stress Echocardiography: localizes ischemia, provides structural information, fast results

- Limited utility with resting RWMA's

Stress Radionuclide Myocardial Perfusion Imaging (rMPI):

- Can quantify involved myocardium and assess viability, good for known CAD
- More expensive, radiation exposure, longer interpretation times; limited utility with balanced ischemia (3-vessel disease)

# Modalities of Stress Testing

---

Which test should I perform?

Factors:

- Institution ability to perform specific test
- Resting ECG
- Patients body habitus
- Exercise capacity
- History of prior revascularization
- Comorbidities (e.g. Asthma, heart failure, valvular disease)
- Radiation exposure



# Coronary CT Angiography

---

**Low to intermediate risk** patients with normal ECG and negative troponins who have potential ACS

- **Sensitivity = 94%, Specificity = 83%**

\*for focal lesions of >70% stenosis when compared with invasive coronary angiography

Potential benefits: reduce unneeded testing, decrease LOS/cost

*“Other than troponin and ECG no need for additional work-up within 2 years of a negative CCTA”- Musey*

Risks: Radiation

# Last thoughts on ED Evaluation

## Guidelines for reasonable and appropriate care in the emergency department (GRACE): Recurrent, low-risk chest pain in the emergency department

Paul I. Musey Jr. MD, MSc, Fernanda Bellolio MD, MS, Suneel Upadhye MD, MSc,



Volume 28, Issue 7  
July 2021  
Pages 718-744

**Recommendation 1:** In adult patients with recurrent, low-risk chest pain, for greater than 3 h duration we suggest a single, high-sensitivity troponin below a validated threshold to reasonably exclude ACS within 30 days. (Conditional, For) [Low level of evidence].

**Recommendation 2:** In adult patients with recurrent, low-risk chest pain, and a normal stress test within the previous 12 months, we do not recommend repeat routine stress testing as a means to decrease rates of MACE at 30 days. (Conditional, Against) [Low level of evidence].

**Recommendation 3:** In adult patients with recurrent, low-risk chest pain, there is insufficient evidence to recommend hospitalization (either standard inpatient admission or observation stay) versus discharge as a strategy to mitigate major adverse cardiac events within 30 days. (No evidence, Either).

**Recommendation 4:** In adult patients with recurrent, low-risk chest pain and non-obstructive (<50% stenosis) CAD on prior angiography within 5 years, we suggest referral for expedited outpatient testing as warranted rather than admission for inpatient evaluation. (Conditional, For) [Low level of evidence].

**Recommendation 5:** In adult patients with recurrent, low-risk chest pain and no occlusive CAD (0% stenosis) on prior angiography within 5 years, we recommend referral for expedited outpatient testing as warranted rather than admission for inpatient evaluation. (Conditional, For) [Low level of evidence].

**Recommendation 6:** In adult patients with recurrent, low-risk chest pain and prior CCTA within the past 2 years with no coronary stenosis, we suggest no further diagnostic testing other than a single, high-sensitivity troponin below a validated threshold to exclude ACS within that 2-year time frame. (Conditional, For) [Moderate level of evidence].

**Recommendation 7:** In adult patients with recurrent, low-risk chest pain, we suggest the use of depression and anxiety screening tools as these might have an effect on healthcare use and return ED visits. (Conditional, Either) [Very low level of evidence].

**Recommendation 8:** In adult patients with recurrent, low-risk chest pain, we suggest referral for anxiety or depression management, as this might have an impact on healthcare use and return ED visits. (Conditional/Either) [Low level of evidence].

# Last thoughts on Office Evaluation

## Acute Chest Pain in Adults: Outpatient Evaluation

AMERICAN FAMILY PHYSICIAN®

*Am Fam Physician.* 2020;102(12):721-727

JOHN R. MCCONAGHY, MD, MALVIKA SHARMA, MD, AND HITEN PATEL, MD

Clinical recommendation	Evidence rating	Comments		
When patients present to the primary care office with chest pain, physicians should consider age, sex, and type of chest pain to predict the likelihood that it is acute coronary syndrome caused by coronary artery disease. <sup>15</sup>	B	Large prospective cohort study	Patients who have chest pain with a low to intermediate probability of coronary artery disease not requiring immediate referral to the emergency department should be evaluated for coronary artery disease with exercise stress testing, coronary computed tomography angiography, or cardiac magnetic resonance imaging. <sup>23-27</sup>	B Unblinded randomized controlled trials and clinical reviews
Physicians should consider using a validated clinical decision rule such as the INTERCHEST rule or the Marburg Heart Score to stratify risk in patients with chest pain. <sup>17-20</sup>	B	Smaller clinical trials of validated decision rules	Patients with localized musculoskeletal pain that is reproducible by palpation or pain reproducible by palpation of the parasternal costochondral joints likely have chest wall pain or costochondritis. <sup>29,30</sup>	C Clinical reviews and consensus expert opinion
Twelve-lead electrocardiography should be performed on all patients in whom cardiac ischemia is suspected. The presence of ST segment changes, new-onset left bundle branch block, presence of Q waves, and new T-wave inversion increases the likelihood of acute coronary syndrome and acute myocardial infarction; these patients should be referred immediately to the emergency department. <sup>21,22</sup>	C	Clinical reviews and consensus expert opinion	Gastroesophageal reflux disease should be considered in patients with burning retrosternal pain, acid regurgitation, and a sour or bitter taste in the mouth. <sup>31,32</sup>	C Clinical review and observational studies
			Panic disorder and anxiety states often cause chest pain and shortness of breath; physicians should consider using a single validated screening question to confirm the diagnosis. <sup>35</sup>	B Validation of a clinical prediction rule

# Back to Mr. N

---

He underwent stress myocardial perfusion imaging. Per his RN, he tolerated the procedure well. He is anxious to discharge .

No myocardial ischemia or infarction.

Mild dilation of left ventricle with mild degree global hypokinesis.  
Post-stress LVEF at 46%.

HISTORY: Chest pain. Coronary artery disease. Status post stent placement.

STRESS STUDY: At baseline, blood pressure was 144/87, with a heart rate of 65 beats per minute. Oxygen saturation was 96%.



Balanced ischemia

# ACS Treatment

---

- MONA is no more...



# ACS Treatment

---

## Step 1: Immediate therapy for ACS

- **OXYGEN**
  - Used for respiratory distress, oxygen saturation <90%
  - “Hyperoxia” has been shown to have a direct vasoconstrictor effect on coronary arteries
- **ASPIRIN**
  - 162-325mg for all patients suspected of ACS
- **NITRATES**
  - Screen for contra-indications (Phosphodiesterase- 5 inhibitors, R Ventricle MI)
  - Only use for patients with active pain
  - IV Nitroglycerin for persistent ischemic pain, HF, or HTN
- **ANALGESICS**
  - **Morphine** used only when other anti-anginals at maximum dose are not relieving CP
  - **NSAIDS** should be discontinued/not initiated because of risk of MACE

# ACS Treatment

---

## Step 2: Therapy for ACS

- **P2Y12 INHIBITORS**
  - **Clopidogrel** 300-600mg loading dose
  - **Ticagrelor** 180mg loading dose
  - **\*Prasugrel** 60mg loading dose
- Load at time of presentation vs. PCI (risk vs. benefit)
- Does your patient potentially need CABG?

# ACS Treatment

---

## Step 2: Therapy for ACS

- **PARENTERAL ANTICOAGULATION THERAPY:**
  - **Unfractionated Heparin (UFH):** continued for 48 hours or until PCI performed
  - **Enoxaparin (LMWH):** for duration of hospitalization or until PCI performed
  - **Fondaparinux (Factor Xa inhibitor):** for duration of hospitalization or until PCI performed
    - Not used as sole anticoagulant
  - **Bivalirudin (Direct thrombin inhibitor):** 0.10 mg/kg loading with 0.25 mg/kg per hour until PCI
    - Similar outcomes to UFH, but less cost effective



# ACS Treatment

---

## Step 3: Decide on a treatment strategy

- **STEMI**: FMC to device time expected to be  $\leq 90$  minutes
- **NSTE-ACS**: Ischemia guided vs. early invasive strategy

# Ischemia-guided vs. Early Invasive Strategy

---

## **Ischemia-guided Strategy**

- Only calls for an invasive evaluation if:
  - patient fails medical therapy (refractory angina)
  - objective evidence of ischemia (dynamic ECG changes, perfusion defect)
  - clinical indicators of very high prognostic risk (e.g. high TIMI or GRACE scores)

## **Early Invasive Strategy (within 24 hours)**

- Triages patients to an invasive diagnostic evaluation (i.e. coronary angiogram)
  - Generally a high-risk patient, or with high-risk features (e.g. + troponin)

Irrespective of strategy chosen, a patient receives optimal anti-ischemic and anti-thrombotic medical therapy

# ACS Treatment

---

## Step 4: Institute routine medical therapy

- **Beta Blockers**: within 24 hours unless contraindicated
- **Statins**: high intensity, regardless of baseline LDL-C
- **ACE/ARB**: LVEF<40%, HTN, DM, stable CKD
- **Aldosterone Antagonist**: if already on therapeutic ACE, BB, and have an LVEF<40%
- **Calcium Channel Blockers**: no benefit; consider only if recurring ischemia, or BB and nitrates are contraindicated or maximized

# Mrs. P

---

48-year-old female with asthma, microcytic anemia secondary to menorrhagia which was due to uterine fibroids who presents to the ED with dyspnea on exertion for 4 weeks. She developed right shoulder and chest pain over the last 4 days.

# Mrs. P

---

## Vitals:

- T 36.5 C; HR 117 bpm; BP 150/94 mmHg; RR 24 br/min; SpO2 95% RA


## Labs:

9.8 /  $\frac{8.9}{30.9}$  / 421


$\frac{135}{4.5}$  |  $\frac{103}{19}$  |  $\frac{16.5}{0.7}$  / 143

hs-cTnT: 5 ng/L (female  $\leq$  10 ng/mL)  
NT-Pro BNP: 6,204 pg/mL (<248 pg/mL)  
D-Dimer: 5,924 ng/mL (< 500 ng/mL\*)

# Ms. P Chest X-ray



# Admission ECG (no priors)



# D-Dimer

---

D-dimer is used as a marker of activation of the coagulation and fibrinolytic systems and indirectly as a marker of thrombotic activity

Causes: VTE, infection, DIC, malignancy, CHF, renal failure, afib, hematologic disease, trauma, age, surgery, pregnancy, smoking

Pro: Low cost

Cons: Poor specificity -> resulting in false positives in low risk patients



# (Modified) Wells Score for PE

Criteria	Scoring
Clinical symptoms of DVT	3.0
Other diagnosis less likely than PE	3.0
HR >100	1.5
Immobilization $\geq$ 3 days or surgery in the previous 4 weeks	1.5
Previous DVT/PE	1.5
Hemoptysis	1.0
Malignancy	1.0

Wells Criteria	Score
High	>6.0
Moderate	2.0 to 6.0
Low	<2.0

Modified Wells Criteria	Score
PE likely	>4.0
PE unlikely	$\leq$ 4.0

# Geneva Score

---

## Risk Factors, symptoms and signs (revised)

- Age 65 +1
- Previous DVT or PE +3
- Surgery or fracture within one month +2
- Active malignancy +2
- Unilateral lower limb pain +3
- Hemoptysis +2
- HR 75 -94 +3
- HR>94 +5
- Deep pain on palpation of one leg or edema +4


## Clinical Probability

Low risk	0-3
Mod risk	4-10
High risk	>11

## Two level Score

PE- Unlikely	0-5
PE- Likely	>6

# CTPA



# PE Treatment

---

**Step 1:** If PE suspected, stabilize the patient while definitive diagnostic test is ongoing


- IV Heparin v. Low Molecular Weight Heparin

**Step 2:** Risk stratification

- High-risk/massive
- Intermediate-risk/submassive
- Low-risk/small

**Hemodynamic instability (“massive PE”):** SBP<90 mmHg for >15 minutes, hypotension requiring vasopressors, or clear evidence of shock

# Massive PE Treatment



# Hemodynamically Stable PE

---

Treat with anticoagulation unless contraindicated:

- Consider IVC Filter
- Consider risk vs. benefit

Consider **thrombolysis** or **catheter-directed thrombolysis** on a case-by-case basis:

- Severe RV dysfunction
- Extensive DVT
- Presence of severe hypoxemia
- Patients who appear to be decompensating but not yet hypotensive
- Clot in transit (RA or RV clot)

# Back to Mrs. P

---

## Transthoracic Echocardiogram:

### Final Impressions

1. Findings consistent with cor pulmonale - possibly acute.
2. Moderate right ventricular enlargement with moderate-severe systolic dysfunction (FAC 26%).
3. Estimated right ventricular systolic pressure 93 mmHg (systolic blood pressure 170 mmHg).
4. Tricuspid annulus dilatation with moderate-severe functional tricuspid regurgitation.
5. Severely dilated inferior vena cava with no inspiratory collapse and dilated hepatic veins.

Underwent emergent **catheter-directed thrombolysis**

# Mrs. P

---

At 24 hours → catheter pulled and placed on heparin drip

- COMPLETE resolution of symptoms!

Transitioned to Xarelto upon discharge

- IUD placed for her vaginal bleeding



# Mr. S

---

65-year-old male with untreated hypertension presents to the ED with acute onset of dizziness and severe chest pain with radiation to his back, of acute onset while he was in the shower. He also described bilateral 9/10 flank pain and nausea & emesis.

# Mr. S

---

## Vitals:

- T 37 C; HR 78; BP 189/99; RR 20 br/min; 96% RA

## Labs:


11.4  $\left\{ \begin{array}{l} 14.7 \\ 42.4 \end{array} \right\}$  175

143	108	17	104
4.1	26	0.9	


hs-cTnT: 8 ng/L (male  $\leq$  15 ng/L)

D-dimer: 1,208 ng/mL (< 500 ng/mL\*)

# Admission ECG



# Chest X-Ray



# Mr. S

---

You are called to see the patient in the ED, so you quickly review his records from when he was admitted to the hospital with atypical chest pain 1 month prior...

# TTE (one month prior):

---

## Final Impressions

1. Normal left ventricular chamber size. Hyperdynamic left ventricular systolic function.
2. Calculated 2-D monoplane volumetric left ventricular ejection fraction 73 %.
3. Mid left ventricular maximal instantaneous Doppler gradient rest 6 mm Hg; Valsalva 28 mm Hg.
4. Concentric remodeling (increased wall thickness to cavity ratio).
5. Findings consistent with normal left ventricular filling pressure.
6. Mild right ventricular enlargement with normal systolic function.
7. Normal left atrial size.
8. No hemodynamically significant valvular heart disease.
9. Normal inferior vena cava size with normal inspiratory collapse (>50%).
10. Mild ascending aorta dilatation (diameter 41 mm at proximal level).
11. No pericardial effusion.

ECG and CXR are unchanged.

# ADD-RS

---

## **Aortic Dissection Detection Risk Score (ADD-RS):**

- 1. High risk conditions:** Marfan syndrome or other CT disease, aortic valvular disease, family history/gene mutation, known thoracic aortic aneurysm, previous cardiac surgery or aortic manipulation


- 1. High risk features:** pain in the chest back or abdomen that is abrupt, severe, or a ripping/tearing sensation

- 1. High risk PE findings:** pulse deficit, SBP difference, focal neurologic deficit, aortic diastolic murmur, shock

**Score 0-3** based on the presence of any positives in each of the categories


- low risk = 0
- intermediate risk = 1
- high risk = 2-3

# ADD-RS with D-dimer





# CT Angiography Chest



# Mr. S

---

CT Angio Chest

CONCLUSION:

1. Type B aortic dissection in the mid descending thoracic aorta with slow flow in the false lumen and intramural hematoma extending into the abdominal aorta. Please see dedicated abdominal CT for detailed intra-abdominal findings.

# Management of Aortic Dissection

## If hypotension or shock:

- IVF bolus +/- vasopressors
- Surgical consultation
- Review/additional imaging studies
  - **Severe AR? Cardiac tamponade?**

## If stable, IV labetalol preferred




- Maintain HR <60, SBP <120 mmHg

## Pain control is essential

- IV morphine reduces force of cardiac contraction

Dissections involving the **ascending thoracic aorta** should have urgent operative or interventional management if able

Classification of aortic dissection

			
Percentage	60%	10–15%	25–30%
Type	DeBakey I	DeBakey II	DeBakey III
	Stanford A (Proximal)		Stanford B (Distal)

# Back to Mr. S

---

Admitted to the ICU, started on esmolol drip + nicardipine drip

**Vascular Surgery consult:** recommended conservative management and serial imaging studies

Complicated hospital course, eventually discharged hospital day 5 on the following regimen:

- labetalol 400mg TID
- lisinopril 40mg QD
- amlodipine 10mg QD
- chlorthalidone 25mg QD

# Take Home Points

---

It is helpful to differentiate cardiac vs. non-cardiac chest pain.

Keep a wide differential...chest pain does not always mean ACS.

Use risk stratification tools, but despite these tools, your clinical judgement is most important!

# References

- Arbab-Zadeh A. Stress testing and non-invasive coronary angiography in patients with suspected coronary artery disease: time for a new paradigm. *Heart International*. 2012;7(1):e2.
- Body et al (2010). The value of symptoms and signs in emergent diagnosis of ACS. *Resuscitation*. 81(3) 281-286.
- Budoff et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter trial. *J Am Coll Cardiol*. 2008;52(21):1724–32.
- Gulati et al. 2021 ACCF/AHA Guideline for evaluation of CP: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 16(1).
- Ferry et al. (2019). Presenting Symptoms in Men and Women Diagnoses with Myocardial Infarction using Sex Specific Criteria. *JAHA* 8(17).
- Haasenritter J, Bösner S, Vaucher P, et al. Ruling out coronary heart disease in primary care: external validation of a clinical prediction rule. *Br J Gen Pract*. 2012;62(599):e416.
- Haasenritter J. Applying a clinical decision rule for CAD in primary care to select a diagnostic test and interpret the results [Point-of-Care Guide]. *Am Fam Physician*. 2019;99(9)
- Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. *N Engl J Med*. 2012;367:299-308.
- Innocenti et al. 2021. D-Dimer Tests in the ED: Current insights. *Emergency Medicine*.
- Kip et al. (2017). The cost-utility of POS troponin testing to diagnose ACS in primary care. *BMC* 213.
- Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. *Eur Heart J*. 2016;37(3):245.
- Kaur, Oliveria- Gomes, Rivera and Gulati (2023). Chest Pain in Women: Considerations from the 2021 AHA/ACC Chest pain guidelines. *Current Problems in Cardiology*. 48(7).
- Kumar et al. (2021). The evolving role of coronary CT angiography in Acute Coronary Syndromes. *Journal of CV CT*. 15(5) 384-393,

# References

Lipinski et al. (2015). Comparison of conventional and HST in patients with CP: A collaborative meta-analysis. *American Heart Journal*. 169(1). 6-16.

Mahajan et al. 2019. Variation and disparities in awareness of MI symptoms among adults in the US. 2(12).

Mangi MA, Rehman H, Bansal V. Ultrasound Assisted Catheter-Directed Thrombolysis of Acute Pulmonary Embolism: A Review of Current Literature. *Cureus*. 2017 Jul; 9(7): e1492

McConaghy et al. (2020) Acute Chest Pain in Adults: Outpatient eval. *American Family Physician*. 102(12).

Meine TJ, R, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. *Am Heart J*. 2005 Jun;149(6):1043-9.

Musey et al. 2021. Guidelines for reasonable and appropriate care in the ED-Grace: Recurrent, low risk chest pain in the ED. *AEM* 28(7)

Nazerian P, Mueller C, Soeiro AM, et al. Diagnostic Accuracy of the Aortic Dissection Detection Risk Score Plus D-Dimer for Acute Aortic Syndromes: The ADVISED Prospective Multicenter Study. *Circulation*. 2018;137(3):250.

Piazza G, Hohlfelder B, Jaff MR, et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: The SEATTLE II study. *JACC Cardiovasc Interv*. 2015;8:1382–1392.

Sandoval et al. (2019). MI risk stratification with a single measurement of hs troponin. *JACC*. 74(3) 271-282.

Salankamenac, Stucki, Keller. (2019). Chest Pain in Repeated ED Visitors. *Journal of Clinical Cardiology*, 1(1).

Smulowitz et al. 2017. Physician Variability in Management of ED patients with chest pain. *Western Journal of Emergency Medicine*. 18(4)

Simon and Ho 2020. Ethnic and Racial disparities in acute MU. *Current Cardiology Reports*. 22(88).

Swap and Nagurney. (2005). Value and limitations of Chest pain history in the evaluation of patients with suspected ACS. *JAMA*. 294 (20). 2633-2629.